Aldeyra Therapeutics Deal History & Licensing Activity
Aldeyra Therapeutics is a biotech headquartered in US. Over the past three years, Aldeyra Therapeutics has been involved in 9 licensing and acquisition transactions, with a primary focus on Small Molecules (11 deals). The company currently has 1 active clinical trial, primarily in Ophthalmology.
Deals (12mo)
2
Active Trials
1
Top Modality
Small Molecules
Focus Area
Ophthalmology
Aldeyra Therapeutics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Aldeyra Therapeutics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| reproxalap | AbbVie | Small Molecules | Phase 3 | option | Apr 2026 |
| reproxalap | AbbVie | Small Molecules | Phase 3 | option | Mar 2026 |
| reproxalap | AbbVie | Small Molecules | Phase 3 | option | Mar 2026 |
Aldeyra Therapeutics Pipeline Focus
Therapeutic areas and modalities where Aldeyra Therapeutics is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Aldeyra Therapeutics Strategic Signals
Key indicators of Aldeyra Therapeutics's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Aldeyra Therapeutics Clinical Pipeline
Aldeyra Therapeutics has 1 active clinical trial across 1 development phase.
1
Phase 3
See How Your Asset Matches Aldeyra Therapeutics's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Ophthalmology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Ophthalmology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for ophthalmology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Aldeyra Therapeutics Licensing & Deal Activity
Aldeyra Therapeutics is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 9 deals over the past three years, Aldeyra Therapeutics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Aldeyra Therapeutics include Ophthalmology (13 deals and trials). In terms of modality, Aldeyra Therapeutics has shown particular interest in small molecules, small molecules, topicalophthalmic.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Aldeyra Therapeutics and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Aldeyra Therapeutics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.